Pfizer has found a leading experimental drug candidate against SARS-CoV-2 and is planning to test the drug in the coming months.
This is according to The Wall Street Journal, which was told the facts by Pfizer’s R&D chief Mikael Dolsten in an interview with the financial paper.
He told the WSJ that early R&D has shown its candidate blocks the new virus, which causes COVID-19, from replicating, with hopes it could slow or stop the spread of the virus in patients with mild to moderate symptoms.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,